Early access
Sign in
Taking people in HungaryPhase 1

Long-term study of RAY121 in adults with several immune-related diseases

Tests RAY121 over a longer time in adults with immune-related diseases.

Key facts

Who runs it
Chugai Pharmaceutical Co. Ltd.
Where
Budapest VIII and Szeged, HungarySee the 2 sitesAlso in 13 other countries, 35 sites
Registry title
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Status
Recruiting
Phase
Phase 1
People taking part
78 people, planned
Started
28 Mar 2025
Expected to end
28 Dec 2026
Type of study
Interventional
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with certain immune diseases to keep taking RAY121 in a long-term extension study. The diseases are antiphospholipid syndrome, dermatomyositis, bullous pemphigoid, Behçet’s syndrome, immune-mediated necrotizing myopathy or immune thrombocytopenia.

Age
18 Years and older
Sex
All sexes can join

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in Hungary

Also in 13 other countries, 35 sites

  • Semmelweis UniversityBudapest VIII, HungaryTaking people
  • University of SzegedSzeged, HungaryTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Long-term study of RAY121 in adults with several immune-related diseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
2 November 2026